wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38251801-B0F4BDE3-CF7C-4C66-9232-C8332E035DC8
Q38251801-B0F4BDE3-CF7C-4C66-9232-C8332E035DC8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38251801-B0F4BDE3-CF7C-4C66-9232-C8332E035DC8
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.
P2860
Q38251801-B0F4BDE3-CF7C-4C66-9232-C8332E035DC8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38251801-B0F4BDE3-CF7C-4C66-9232-C8332E035DC8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1f978ccc7792ff9aae8bab4fa6d8a504d0f1e535
P2860
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.